Evercore ISI Issues Positive Forecast for Immunome (NASDAQ:IMNM) Stock Price

Immunome (NASDAQ:IMNM) had its target price upped by investment analysts at Evercore ISI from $18.00 to $40.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Evercore ISI’s price target suggests a potential upside of 73.01% from the stock’s current price.

A number of other equities research analysts have also weighed in on IMNM. Leerink Partners set a $40.00 target price on shares of Immunome in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Guggenheim increased their target price on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday. The Goldman Sachs Group initiated coverage on Immunome in a research note on Monday, September 22nd. They set a “buy” rating and a $26.00 price target for the company. Finally, Craig Hallum started coverage on shares of Immunome in a research report on Friday, September 5th. They set a “buy” rating and a $26.00 price target for the company. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Immunome currently has an average rating of “Moderate Buy” and a consensus price target of $29.27.

Immunome Stock Performance

IMNM opened at $23.12 on Tuesday. The company’s 50-day simple moving average is $17.11 and its two-hundred day simple moving average is $12.39. The stock has a market capitalization of $2.12 billion, a P/E ratio of -7.87 and a beta of 2.17. Immunome has a 52-week low of $5.15 and a 52-week high of $25.30.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Research analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Assetmark Inc. bought a new position in Immunome in the 3rd quarter worth approximately $39,000. BNP Paribas Financial Markets lifted its holdings in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the last quarter. BIT Capital GmbH bought a new position in shares of Immunome during the third quarter worth $69,000. Finally, Russell Investments Group Ltd. purchased a new position in Immunome during the third quarter valued at $76,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.